行政院國家科學委員會專題研究計畫成果報告:合併使用FK 506及LEFLUNOMIDE在大鼠肢體移植上之研究
Date Issued
1998
Date
1998
Author(s)
葉力森
DOI
872313B002095
Abstract
Whole limb allotransplantation
presents a tremendous immunologic
challenge due to the antigenicity of skin,
muscle and bone marrow. In our previous
study, leflunomide (LEF) combined with
cyclosporine (CsA) prevented limb allograft
rejection across a strong histocompatibility
barrier. Using the same model, LEF plus
FK506, a new immunosuppressant with
higher efficiency than CsA, was
administered to rats receiving vascularized
osteo-myo-cutaneous allografts.
Vascularized osteo-myo-cutaneous of rear
limbs were transplanted from Brown-
Norway to Lewis rat recipients. Recipients
were administered LEF (10 mg/kg/24hr/PO)
and FK506 (0.1 or 0.5 mg/kg/24hr/SC) or
CsA (Neoral, 5mg/kg/24hr/PO) starting 1
days prior to surgery. Treatment continued
for 30 days or until graft rejection. All
treated allografts survived the 30 day period
without signs of rejection and GVHD. In
the group treated with FK506 0.1mg/kg,
75% recipients showed rejection 20 days
after cessation of treatment. No rejection
presented in those recipients treated with
FK506 0.5mg/kg over 100 days after
cessation of treatment. All recipients
treated by CsA showed rejection within 2
week after cessation of treatment.
According to the result of this research,
combination of LEF and FK506 can induce
immune tolerance in the high antigenetic
limb transplantation. We never review
similar report in other article.
Subjects
肢體移植
排斥
移植物宿主病
Publisher
臺北市：國立臺灣大學獸醫學系暨研究所
Type
report
File(s)![Thumbnail Image]()
Loading...
Name
872313B002095.pdf
Size
49 KB
Format
Adobe PDF
Checksum
(MD5):19442abc45d740524195813bb435b658